FDA OK’s Emergent BioSolutions plant to resume manufacturing J&J’s Covid vaccine

Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson’s Covid-19 vaccine.

Exit mobile version